Sexual health / Research index
PT-141
PT-141 is the development name associated with bremelanotide, a peptide acting at melanocortin receptors. Interpreting its literature requires separating sexual desire, associated distress and other outcomes. These measures answer different questions and are not interchangeable descriptions of sexual performance.
Names used in the literature: PT-141 · Bremelanotide · Bremelanotida
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
PT-141 10 mg
- Presentation
- 10 mg
- Catalog reference
- PMX-PT141-10
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
How the clinical question was defined
A phase 2 trial studied bremelanotide in premenopausal women with sexual dysfunction. It evaluated satisfying sexual events and scales measuring function and distress. These endpoints describe particular experiences and symptoms in a selected population; they do not establish the compound as a universal enhancer of sexual performance.
Sources: [1]
What the RECONNECT studies assessed
Two phase 3 trials compared bremelanotide with placebo in premenopausal women with hypoactive sexual desire disorder. Their main endpoints concerned desire and distress associated with low desire. Results favored treatment on those scales; nausea, flushing and headache were also reported more frequently. The outcomes therefore require both benefit and tolerability context.
Sources: [2]
The medicine’s formulation matters
The U.S. Vyleesi label defines a specific indication and patient population. Evidence and authorization for that medicine belong to its evaluated formulation. A catalog vial identified as PT-141 does not acquire pharmaceutical equivalence, demonstrated quality or authorization merely by sharing the active ingredient’s name. Product-level evidence remains a separate question.
Sources: [3]
Questions about this reference
Do these studies establish a general benefit in men and women?
No. The cited phase 3 studies focused on premenopausal women with a defined diagnosis. Their findings do not automatically extend to men, other age groups, or every form of sexual difficulty.
Is the catalog’s PT-141 the same product as Vyleesi?
The compound name does not demonstrate finished-product equivalence. Vyleesi has a documented composition and presentation. Matching names does not verify those characteristics in another vial or establish its regulatory status in Mexico.
Sources and original reading
- Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
- VYLEESI — bremelanotide prescribing information
Content updated: . How this content is prepared and checked.
Understand before comparing